Obermiller PS - Search Results

1

A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer.

Tait DL, Obermiller PS, Redlin-Frazier S, Jensen RA, Welcsh P, Dann J, King MC, Johnson DH, Holt JT. Tait DL, et al. Among authors: obermiller ps. Clin Cancer Res. 1997 Nov;3(11):1959-68. Clin Cancer Res. 1997. PMID: 9815585 Clinical Trial.

2

Ovarian cancer gene therapy.

Tait DL, Obermiller PS, Jensen RA, Holt JT. Tait DL, et al. Among authors: obermiller ps. Hematol Oncol Clin North Am. 1998 Jun;12(3):539-52. doi: 10.1016/s0889-8588(05)70007-1. Hematol Oncol Clin North Am. 1998. PMID: 9684097 Review.

3

Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability.

Tait DL, Obermiller PS, Hatmaker AR, Redlin-Frazier S, Holt JT. Tait DL, et al. Among authors: obermiller ps. Clin Cancer Res. 1999 Jul;5(7):1708-14. Clin Cancer Res. 1999. PMID: 10430073 Clinical Trial.

4

Gene therapy for carcinoma of the breast: Therapeutic genetic correction strategies.

Obermiller PS, Tait DL, Holt JT. Obermiller PS, et al. Breast Cancer Res. 2000;2(1):28-31. doi: 10.1186/bcr26. Epub 1999 Dec 17. Breast Cancer Res. 2000. PMID: 11250690 Free PMC article. Review.

5

Ovarian Cancer Gene Therapy with BRCA1-An Overview.

Obermiller PS, Holt JT. Obermiller PS, et al. Methods Mol Med. 2000;35:593-607. doi: 10.1385/1-59259-086-1:593. Methods Mol Med. 2000. PMID: 21390833

6

Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression.

Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Thompson ME, et al. Among authors: obermiller ps. Nat Genet. 1995 Apr;9(4):444-50. doi: 10.1038/ng0495-444. Nat Genet. 1995. PMID: 7795653

7

Preclinical studies of a new generation retroviral vector for ovarian cancer BRCA1 gene therapy.

Tait DL, Obermiller PS, Holt JT. Tait DL, et al. Among authors: obermiller ps. Gynecol Oncol. 2000 Dec;79(3):471-6. doi: 10.1006/gyno.2000.5969. Gynecol Oncol. 2000. PMID: 11104622

8

Activation-driven T cell death. II. Quantitative differences alone distinguish stimuli triggering nontransformed T cell proliferation or death.

Ucker DS, Meyers J, Obermiller PS. Ucker DS, et al. Among authors: obermiller ps. J Immunol. 1992 Sep 1;149(5):1583-92. J Immunol. 1992. PMID: 1380534

9

Genome digestion is a dispensable consequence of physiological cell death mediated by cytotoxic T lymphocytes.

Ucker DS, Obermiller PS, Eckhart W, Apgar JR, Berger NA, Meyers J. Ucker DS, et al. Among authors: obermiller ps. Mol Cell Biol. 1992 Jul;12(7):3060-9. doi: 10.1128/mcb.12.7.3060-3069.1992. Mol Cell Biol. 1992. PMID: 1620115 Free PMC article.

10

Introduction and expression of the bacterial PaeR7 restriction endonuclease gene in mouse cells containing the PaeR7 methylase.

Kwoh TJ, Obermiller PS, McCue AW, Kwoh DY, Sullivan SA, Gingeras TR. Kwoh TJ, et al. Among authors: obermiller ps. Nucleic Acids Res. 1988 Dec 23;16(24):11489-506. doi: 10.1093/nar/16.24.11489. Nucleic Acids Res. 1988. PMID: 2850539 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

11 results

Search Page

Filters